http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#Head
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#assertion
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#provenance
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#pubinfo
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#assertion
http://purl.obolibrary.org/obo/DOID_2349
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_2349
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB01255
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#association
http://www.w3.org/2000/01/rdf-schema#label
"Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncratic reaction to sympathomimetic amines, glaucoma Agitated states Patients with a history of drug abuse During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result) [ See Drug Interactions (7.3) Advanced arteriosclerosis ( 4 Symptomatic cardiovascular disease ( 4 Moderate to severe hypertension ( 4 Hyperthyroidism ( 4 Known hypersensitivity or idiosyncrasy to sympathomimetic amines ( 4 Glaucoma ( 4 Agitated states ( 4 History of drug abuse ( 4 During or within 14 days following the administration of monoamine oxidase inhibitors (MAOI) ( 4 7.3"
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB01255
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#provenance
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#pubinfo
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#sig
http://purl.org/nanopub/x/hasSignature
aho1PoHFhoJFojcpMyQKZGb7HKyl149YlzPcaYrfwnZ81Sun1SF3GpfuHs5Jbdz5PsbPnsoShdoD7MDUAz3IHjncWvIhWhezpBs5DKHKs4M7Xbsckl0AjhHeTFOtdDLCA4eXJ3b96Ey6ZG7X4xbTyLkxhy6pSILf7RrHvn7S7iM=
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU
http://purl.org/dc/terms/created
2021-08-23T13:00:18.351+02:00
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAU7Sz6lsz8n_q_7AO3X6w6MgoSdAyw0XwJNb1AWGexqU
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY